Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

about

Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

Item

http://www.wikidata.org/entity/Q50564520

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@en

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@nl

type

Item

label

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@en

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@nl

prefLabel

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@en

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@nl

P1476

Rifaximin Re-treatment in Pati ...... me: Feels Like the First Time?

@en

P2093

Antonio Gasbarrini

http://www.w3.org/2001/XMLSchema#string

Francesca Romana Ponziani

http://www.w3.org/2001/XMLSchema#string

Maurizio Pompili

http://www.w3.org/2001/XMLSchema#string

P2860

Rifaximin therapy for patients with irritable bowel syndrome without constipation

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.

Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

The Intestinal Microbiota and Irritable Bowel Syndrome.

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin.

Irritable bowel syndrome

P2888

s10620-017-4656-1

P304

2220-2222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1007/S10620-017-4656-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28646286

http://www.w3.org/2001/XMLSchema#string